Print   



BEXIMCO PHARMACEUTICALS LTD.

News Release

20 May, 2009

Beximco Pharmaceuticals exports Oseltamivir capsules to 

Latin and Central America

Beximco Pharmaceuticals Ltd. ('BPL' or the 'Company') today announces that it has commenced supplying Oseltamivir capsules, Oseflu® (BPL's generic version of Tamiflu®), to Latin and Central American countries, the regions most affected by the recent H1N1 swine flu (influenza A) outbreak.

The World Health Organization ('WHO') estimate that 39 countries have officially reported 8,480 cases of influenza A (H1N1) infection, (WHO update 31, 17 May 2009). H1N1 appears to be more contagious than seasonal influenza and the new virus causing swine flu has been found to respond positively to Oseltamivir treatment.

Nazmul Hassan, Managing Director of Beximco Pharmaceuticals, commented:  

'BPL is the first company from Bangladesh to help combat the swine flu outbreak in Latin & Central American countries. The Company has already supplied Oseflu® stocks to the Ministry of Health in Chile and Belize, as well as to high profile
Government and non-Government agencies. We look forward to helping to combat this virus which has already affected many people across the world.'

Beximco Pharmaceuticals introduced Oseltamivir capsule Oseflu® in 2006 for the prevention and treatment of influenza including swine and bird flu. In the same year BPL supplied Oseflu® to the Bangladesh and Myanmar Governments for stockpiling to combat the Bird flu pandemic. The Company has increased its Oseflu® stock to ensure further supply into other countries in the near future.

-Ends-

For further information please visit www.beximco-pharma.com or enquire to:

Beximco Pharma

Nazmul Hassan, CEO/MD

Tel: +880 2 861 9151, ext.2080

Libertas Capital Corporate Finance

Jakob Kinde / Anthony Rowland

Tel: +44 (0)20 7569 9650

Financial Dynamics

Jonathan Birt / Susan Quigley

Tel: +44 (0)20 7269 7169

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff. 

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.

ENDNRASFIFDASUSEII